Other Events ·
POMDOCTOR terminates ADR program, consolidates shares 10-for-1 ahead of Nasdaq relisting
POMPOMDOCTOR Ltd
POMDOCTOR Limited has commenced the termination of its American Depositary Receipt (ADR) program and related deposit agreement, following prior board and shareholder approval. The ADR Program is expected to terminate prior to market open on October 21, 2026, at which point ADSs will be mandatorily cancelled and exchanged for Class A ordinary shares. Simultaneously, the company will effect a share consolidation where every ten ordinary shares of each class are consolidated into one. Consequently, holders of ten ADSs will receive three post-consolidation Class A ordinary shares. The company plans to list its Class A ordinary shares on Nasdaq under the symbol "POM" starting October 21, 2026. POMDOCTOR Limited operates in the healthcare and medical technology sector.